Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 42B22 | — |
adult female patient received Engerix-B pediatric first dose; adult female patient received Engerix-B pediatric first dose; This non-serious case was reported by a nurse via call center representative and described the occurrence of underdose in a 47-year-old female patient who received HBV (Engerix B pediatric) (batch number 42B22, expiry date 07-MAR-2026) for prophylaxis. On 27-MAR-2025, the patient received the 1st dose of Engerix B pediatric. On 27-MAR-2025, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: adult female patient received Engerix-B pediatric first dose) and adult use of a child product (Verbatim: adult female patient received Engerix-B pediatric first dose). The outcome of the underdose and adult use of a child product were not applicable. Additional Information: GSK Receipt Date: 27-MAR-2025 The nurse reported that, on the day of reporting, an adult patient received Engerix-B pediatric first dose, which led to an underdose and adult use of a child product. The vaccine administration facility was the same as primary reporter.